PrimeRFP - AI-Powered RFP Solutions
PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91018F00077 — CELL-BASED IMMUNOTHERAPY PRODUCTS

CELL-BASED IMMUNOTHERAPY PRODUCTS is a federal award for Department of Health and Human Services (HHS) held by LEIDOS BIOMEDICAL RESEARCH, INC.. Estimated value $53.5M ($20.2M obligated). Current period of performance ends Aug 29, 2029. Place of performance: FREDERICK MD. Related solicitation N01CO5240180.

$53.5M
Estimated Value
$20.2M
Obligated
Aug 29, 2029
PoP End / Expires

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

LEIDOS BIOMEDICAL RESEARCH, INC. holds $2.3B across 187 federal awards, concentrated at Department of Health and Human Services (HHS). Recompete timing centers on the Aug 29, 2029 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

Federal
Contract number75N91018F00077
AgencyDepartment of Health and Human Services (HHS)
IncumbentLEIDOS BIOMEDICAL RESEARCH, INC.
CAGE3LYK6
UEIHV8BH9BPG8Y9
NAICS561210

No full NAICS 561210 intel page yet. Browse NAICS intelligence

PSCM1HA
Parent IDIQ / IDVHHSN261201500003I
Place of performanceFREDERICK MD
Pricing typeCost Plus Fixed Fee
Extent competedNot Competed
Related solicitationN01CO5240180
PoP startSep 24, 2018
PoP end (current)Aug 29, 2029
Obligated$20.2M
Current value$53.5M
Potential value$53.5M

Recompete timing

Public
● Expiring in 1108 days

Current PoP ends Aug 29, 2029 (1108 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Feb 29, 2028.

Watch this contract — one email →

Incumbent footprint

Public record

LEIDOS BIOMEDICAL RESEARCH, INC. — $2.3B obligated across 187 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$2.3B · 100% of firm total
Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open LEIDOS BIOMEDICAL RESEARCH, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75N91018F00077?

75N91018F00077 (CELL-BASED IMMUNOTHERAPY PRODUCTS) is a Department of Health and Human Services (HHS) award with an estimated value of $53.5M, currently held by LEIDOS BIOMEDICAL RESEARCH, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75N91018F00077?

LEIDOS BIOMEDICAL RESEARCH, INC. is the incumbent with $2.3B across 187 related awards in SCOUT’s public footprint. The current period of performance ends Aug 29, 2029.

When does 75N91018F00077 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 29, 2029. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HHSN261201500003I-75N91018F00077